A new study has found that the inhibitor present in an enzyme called ACVR1 can slow down the tumor growth. It can also increase the life expectancy in children suffering from Diffuse Intrinsic Pontine Glioma (DIPG) which is the most fatal brain tumor among children.
The study was published in Nature Communications on March 4, 2019.
According to the reports, Histone is a protein which keeps the six-foot-long DNA strand intact in a tiny nucleus of every cell. It is also responsible for regulating the genes if anything goes wrong during histone mutation.
Researchers for the first time showcase the study on an animal model by combining ACVR1 enzyme mutation with histone mutation in 20 percent of DIPGs. The combination of these two mutations is essential for processing tumor growth.
There are no currently approved medicine for the treatment of DIPG available in the market. Researchers claim that this study might open the doors for its new treatment.
Oren Becher, senior author of this study and Associate Professor of Pediatrics at Northwestern University Feinberg School of Medicine, said, “Our results are encouraging and suggest that it might be reasonable to test an inhibitor of this enzyme in a clinical trial.”
He added, “Prior to that, we need to evaluate different ACVR1 inhibitors in animal models to make sure we bring the most safe and effective agent to trials with children.”
The researchers of Manne Research Institute have emphasized on improving the health of children. According to them, more research is needed to be done on howabouts of ACVR1 and histone mutation combination which can accelerate the growth of tumor cell. More scientific knowledge will help them treat children suffering from DIPG better.